52 results about "Epithelial carcinoma" patented technology

The invention provides a reagent for diagnosing cervical cancer, which can not only detect the presence or absence of cervical cancer but can also distinguish squamous cell carcinoma and adenocarcinoma from each other, a method for screening cervical cancer by using the reagent, particularly a screening method capable high speed processing by utilizing flow cytometry. The reagent comprises a first labeled antibody reacting with gland cells, a second labeled antibody reacting with adenocarcinoma cells and a third labeled antibody reacting with atypical cervical squamous cells, the antibodies being labeled with mutually distinguishable labels respectively. Preferably, at least one selected from the group consisting of MUC1 antibody, cytokeratin 7 antibody, and cytokeratin 18 antibody is used as the first labeled antibody, at least one selected from the group consisting of cytokeratin 8 antibody and HIK1083 antibody is used as the second labeled antibody, and at least one member selected from the group consisting of NMP179 antibody, p16[INK4A] antibody, Ki-67 antibody, p53 antibody, p21 antibody, EMA antibody, CEA antibody and MIB-1 antibody is used as the third labeled antibody.

The present invention relates to methods of prognosing urothelial carcinoma. In one embodiment, the present invention provides a method of prognosing urothelial carcinoma by determining expression levels of JUN, MAP2K6, STAT3 and / or ICAM1. In another embodiment, the present invention provides an single prognostic panel made up of eight gene markers. In another embodiment, the present invention provides a single prognostic panel made up of eleven gene markers.

The present invention relates to a yew branch and leaf extract, an extraction method and applications thereof. The yew branch and leaf extract is extracted by adopting branches and leaves of Taxus chinensis var. mairei as raw materials, and comprises cephalomannine and 7-epitaxol, wherein the active ingredients provide an inhabitation effect for squamous cells in skin cancers, and especially provide significant treatment effects for anal squamous cell carcinoma, esophagus squamous carcinoma and tonsil squamous cell carcinoma. According to the present invention, resource advantages of the yew are utilized to deep develop, utilize and research the Taxus chinensis var. mairei; and a yew anti-skin cancer component extraction method with a characteristic of simple operation is provided, and an effect of the component in anti-skin cancer application is determined.

Disclosed are an Hsp90 inhibitor and a preparation method and use thereof. The Hsp90 inhibitor is 2-(4-(3-acetylcarnitineacyloxy)cyclohexylamino)-4-(1-(3,6,6-trimethyl-4-oxy-4,5,6,7-tetrahydroindazole))benzamide. The Hsp90 inhibitor has good water solubility and high bioavailability, and can effectively inhibit the proliferation of cancer cells, such as leukemia, cervical cancer, breast cancer, human laryngeal epithelial carcinoma, or malignant melanoma cells. It can also effectively inhibit the activity of herpes simplex virus. The maximal non-toxic concentration of the Hsp90 inhibitor on normal cells is a high, and the Hsp90 inhibitor only has specific inhibition effect on cancer cells.

The invention discloses an application of YTHDF2 in diagnosis, prevention and treatment of urothelium carcinoma. The invention discloses the application of a reagent for detecting YTHDF2 gene in preparing products for diagnosing urothelium carcinoma and also discloses the application of an inhibitor of YTHDF2 gene expression in preparing drugs for treating or preventing urothelium carcinoma. The invention firstly confirms the function of YTHDF2 in urothelium carcinoma; expression quantity of YTHDF2 in urothelium carcinoma tissues is up-regulated and multiplication and migration of urothelium carcinoma cells are promoted; YTHDF2 can be used as a potential target for diagnosing and treating clinic urothelium carcinoma.

The present invention relates to antibodies that have specificity towards prolactin binding protein (PRLBP) that is either bound to a binding partner or unbound to a binding partner, as well as antibodies towards PRLBP regardless of the binding state of PRLBP. The present invention also provides methods of using these PRLBP-specific antibodies, such as method of diagnosing and monitoring the progression of diseases such as epithelial carcinomas, osteoporosis, infertility and cachexia.

A flaviviral replicon-based construct is provided for delivery and expression of granulocyte-macrophage colony stimulating factor to facilitate tumour therapy. In particular, the replicon construct encodes a Kunjin virus replicon having one or more mutations in an NS2A non-structural protein that induce enhanced levels of cellular IFN that synergize with recombinant granulocyte-macrophage colony stimulating factor delivered according to the invention. The construct may be administered intra-tumourally or peri-tumourally to an animal as DNA, RNA or packaged into a VLP, for the therapeutic and / or prophylactic treatment of tumours and cancers such as melanoma, lung carcinoma, cervical carcinoma, lung epithelial carcinoma, prostate cancer, breast cancer, renal carcinoma, colon cancer, epithelial cancers and mesothelioma.

The invention relates to the field of biotechnology and medical diagnosis, in particular to a detection method and a kit for diagnosing bladder urothelium carcinoma. The invention provides application of a primer combination for detecting a DNA methylation difference region in a to-be-detected sample in preparation of a reagent or a kit for detecting or predicting whether a subject suffers from bladder urinary tract epithelial carcinoma or not or whether a bladder urinary tract epithelial carcinoma patient typing is muscular layer wetting or non-muscular layer wetting or not. The invention also relates to a kit for detecting or predicting whether a subject suffers from the bladder urothelial carcinoma or whether a bladder urothelial carcinoma patient typing is muscular layer infiltration or non-muscular layer infiltration. The detection method and the kit for diagnosing the bladder urinary tract epithelium cancer, provided by the invention, have excellent sensitivity and specificity, have great positive significance on clinical diagnosis and treatment of the bladder urinary tract epithelium cancer and later monitoring and prognosis evaluation, and provide a theoretical basis for further early diagnosis.

This invention relates to a method for detecting urothelial carcinoma using an antibody that specifically reacts with a calreticulin protein or a fragment thereof and immunoassaying a calreticulin protein in a sample.

The invention provides a monoclonal antibody for recognizing HPV16 positive cervical epithelial cancer cells, and applications thereof, wherein the antibody can specifically detect the cervical cancer biomarker HPV16E7 protein in tumor cells so as to distinguish the cancerous cervical epithelial cells and the cervical abnormality or non-cancerous cervical epithelial cells, such that the basis can be provided for doctors so as to accurately diagnose the cancer caused by HPV infection, the missed diagnosis rate of the high-grade cervical lesion can be effectively reduced, the sufficient time and the basis can be provided for the clinical doctor to diagnose and treat the patients, and the early cervical disease detection and the early intervention can be improved; and with the monoclonal antibody, the unnecessary colposcopy can be reduced and avoided.

The invention relates to methods for locally delivering a chemotherapeutic agent to an upper tract urothelial carcinoma (UTUC). The methods involve placing a balloon catheter that has a working channel and a balloon into the ureter / renal pelvis via retrograde or antegrade ureteral access; inflating the catheter balloon to temporarily obstruct the ureter; infusing (instilling) a liposomal formulation that includes a chemotherapeutic agent into the working channel of the catheter; and allowing the infused liposomal formulation to dwell in the ureter and / or renal pelvis for a time sufficient to allow at least a portion of the liposomal formulation to adhere to the urothelial wall. In the methods of the invention, at least a portion of the infused chemotherapeutic-agent formulation adheres tothe urothelial wall while it is instilled and dwells in the ureter and / or renal pelvis. The disclosed methods can be performed as an adjuvant therapy to other methods of treating UTUC, such as ureteroscopic ablation or resection of the tumor.

The invention relates to 4-deoxidized-iso-podophyllotoxin derivatives displayed by formula (1) and the intermediate series of compounds of 4-deoxidized-iso-podophyllotoxin derivatives or the pharmaceutical salt or solvates of the 4-deoxidized-iso-podophyllotoxin derivatives. The invention also relates to the preparation method, the drug combinations, and the pharmaceutical applications of compounds in the formula (1). The compounds possess strong activity in inhibiting tumor cell growth, some of which having stronger cytotoxic activity to human body tumor cell lines in vitro than etoposide, the prior first class anti-tumor drug, thereby the compounds are expected to serve the purpose of such cancer drugs as anti-lung cancer drugs, anti-hepatoma drugs, and anti-cerbical cancer drugs; since the cytotoxicity of the related compounds to KB cells and PC-3 cells is approximate to or equivalent to etoposide, and meanwhile the compounds have strong etoposide to CNE cells, the compounds are expected to used in anti-tumor drugs, such as, anti-oral epithelial carcinoma drugs, nasopharyngeal carcinoma drugs, and prostate cancer drugs.

The present invention provides methods, devices, and kits related to treatment of urothelial carcinomas of the lower tract with antimetabolite (such as gemcitabine). In some aspects the methods, devices and kits relate to treatment of urothelial carcinomas of the lower tract with an antimetabolite (such as gemcitabine) and an immunomodulating agent.

The present invention provides a monoclonal antibody capable of recognizing high-risk HPV E7 positive cervical epithelial cancer cells, and applications thereof. According to the present invention, the monoclonal antibody can highly specifically detect cervical cancer biomarkers HPV E7 protein in tumor cells, wherein the cervical cancer biomarker HPV E7 protein covers HPV16, HPV31, HPV35, HPV52 and HPV58 and other high-risk subtypes, such that cancerous cervical epithelial cells and abnormal cervix or non-cancerous cervical epithelial cells can be distinguishes so as to provide basis for the accurate diagnosis of HPV infection-induced cancers, effectively reduce the missed diagnosis of high-grade cervical lesions, provide complete time and complete basis for the diagnosis and the treatmentof patients by clinicians, improve the detection of early-stage cervical diseases and the early intervention, and reduce and avoid unnecessary colposcopy.

This invention relates to methods of distinguishing among various types of differentiated and undifferentiated epithelial carcinomas, and non-epithelial carcinomas, by detecting the presence of p63 nucleic acid or protein expression. The invention also provides methods for detecting p63 nucleic acids and proteins, as well as methods for diagnosing and treating certain tumors based on whether the tumors express p63.

The invention locally delivers a chemotherapeutic or a radiographic contrast agent to an upper tract urothelial carcinoma (UTUC). The invention includes a balloon catheter with a working channel and aballoon placed into the ureter / renal pelvis via retrograde or antegrade ureteral access. The balloon is inflated to temporarily obstruct the ureter, and a formulation with a chemotherapeutic agent isinfused into the working channel of the catheter and allowed to dwell in the ureter / renal pelvis for a time sufficient to allow the formulation to adhere to and penetrate the urothelial wall. The formulations can be liposomal or non-liposomal formulations. At least a portion of the infused chemotherapeutic-agent formulation adheres to the urothelial wall while it is instilled and dwells in the ureter / renal pelvis. The methods of the invention can be performed as an adjuvant therapy to other methods of treating UTUC, including ureteroscopic ablation or resection of the tumor.

The invention discloses application of VEGF-C in screening of medicine for diagnosing or treating implantation metastasis cancer, and belongs to the field of medicine. It is proved that TAM relevant spheroids and the ovarian cancer clinical pathology are closely connected, an ovarian epithelial cancer model established in a mouse indicates that TAM promotes spheroid forming and tumor growing in the ovarian cancer implantation metastasis early stage, after EGF excreted by TAM activates EGFR on tumor cells, the EGF up-regulates tumor cells VEGFs-VEGFRs pathway signal transduction in return and then promotes tumor cell proliferation and differentiation, the EGF can up-regulate expression of alphaMbeta2 integral protein on TAM and expression of ICAM-1 on the tumor cells, and the tumor cell-TAM association is promoted. After TAM or medicine retardant VEGF or ICAM-1 in antibodies are removed from the rat, spheroid forming and ovarian cancer progression are hindered. A new mechanism of TAM mediated spheroids is disclosed, and new targeted therapy is provided for ovarian cancer and other distant metastatic cancer.

This invention relates to methods of distinguishing among various types of differentiated and undifferentiated epithelial carcinomas, and non-epithelial carcinomas, by detecting the presence of p63 nucleic acid or protein expression. The invention also provides methods for detecting p63 nucleic acids and proteins, as well as methods for diagnosing and treating certain tumors based on whether the tumors express p63.

It is to provide a method for detecting urothelial cancer simply and with high accuracy. It is a method for detecting urothelial cancer comprising administering 5-aminolevulinic acid (ALA), a derivative thereof, or a salt of these to a test subject, collecting urine from the test subject, and detecting the presence of fluorescence or amount of fluorescence in the collected urine.

The invention discloses a method for culturing upper urinary tract urothelial cell carcinoma organoids. The method comprises the following steps: placing small upper urinary tract urothelial cell carcinoma tissue blocks in an inhibitor containing type II collagenase for first digestion treatment to obtain a first digest; placing the first digest in a pancreatin substitute containing an inhibitor, and performing second digestion treatment to obtain a second digest; sequentially performing first neutralization treatment, filtering treatment and centrifugal treatment on the second digest to obtain single cell precipitate; placing the single cell precipitate in a mixed substrate of a preset culture medium and substrate glue for resuspension treatment to obtain a gel suspension containing all cells; and culturing the gel suspension according to a preset scheme to obtain the upper urinary tract urothelial cell carcinoma organoids. According to the scheme, reliable clinical data can be provided for use of chemotherapeutic drugs and personalized treatment of upper urinary tract urothelial cell tumors.

This invention relates to a liquid pharmaceutical composition comprising cabozantinib to treat locally advanced or metastatic solid tumors, particularly advanced urothelial cancer or renal cell carcinoma in patients in need thereof.

The invention relates to methods for locally delivering a chemotherapeutic agent to an upper tract urothelial carcinoma (UTUC). The methods involve placing a balloon catheter that has a working channel and a balloon into the ureter / renal pelvis via retrograde or antegrade ureteral access; inflating the catheter balloon to temporarily obstruct the ureter; infusing (instilling) a liposomal formulation that includes a chemotherapeutic agent into the working channel of the catheter; and allowing the infused liposomal formulation to dwell in the ureter and / or renal pelvis for a time sufficient to allow at least a portion of the liposomal formulation to adhere to the urothelial wall. In the methods of the invention, at least a portion of the infused chemotherapeutic-agent formulation adheres to the urothelial wall while it is instilled and dwells in the ureter and / or renal pelvis. The disclosed methods can be performed as an adjuvant therapy to other methods of treating UTUC, such as ureteroscopic ablation or resection of the tumor.

Diagnostic assays for medically classifying cancer patients are provided. The method comprises assessing a tissue sample of the patient for the presence of a copy number gain of chromosome regions 1q23.3 and / or 1q21.2. Copy number gain of chromosome regions 1q23.3 and / or 1q21.2 is indicative of a less favorable prognosis as compared to the prognosis if there was no copy number gain in the same regions.

Described herein methods of treating urothelial carcinoma with an approved drug product containing a fibroblast growth factor receptor (FGFR) inhibitor. Also described herein are methods of selling or offering for sale an approved drug product containing a fibroblast growth factor receptor (FGFR) inhibitor.

The invention discloses a urine detection kit for diagnosing urothelium carcinoma. The urine detection kit comprises capture reagent, detection reagent, coating buffer solution, scrubbing solution, color-producing reagent and termination reagent. The capture reagent is anti-Neu5Gc primary antibody, and the detection agent is anti-Neu5Gc second antibody. The kit disclosed by the invention is high in sensitivity and has the advantage of the urine exfoliocytology, the problem that the urine exfoliocytology is low in sensitivity is overcome, and the kit can be used for the early screening of the urothelium carcinoma.

The invention relates to a homogeneous immunoassay reagent kit for detecting beta human chorionic gonadotropin in the technical field of immunoassay, and a preparation method and application thereof. The homogeneous immunodetection reagent kit for β-human chorionic gonadotropin obtained by the method provided by the present invention has a wide range of signal values ​​when analyzed by the photo-excited chemiluminescence immunoassay platform, and reaches the quantitative test standard; the sensitivity is high, and can be accurately detected. The serum or urine β-hCG level is used for in vitro diagnosis; it has good stability and high precision; and by optimizing the analysis system (antibody dosage and buffer solution, etc.), the analysis performance meets the industry standard, which is used for clinical pregnancy diagnosis and dynamic monitoring of hydatidiform mole and hydatidiform mole. Provide reference for the therapeutic effect of choriocarcinoma.

The invention relates to the discovery and application of a plurality of drug lead compounds, in particular to a bis-substituted allyl benzene compound with cytotoxic activity, the key intermediate and the pharmaceutical salt of the compound, also to the preparation method, the drug composition and the medicinal purpose of the allyl benzene derivative and the key intermediate of the allyl benzenederivative, belonging to the fields of organic chemistry, medicinal chemistry and pharmacology. The compound of the discovery in vitro inhibits the activity of six human tumor cell lines-human prostate cancer cells (PC-3), nasopharyngeal carcinoma cells (CNE), oral epithelial carcinoma cells (KB), human lung cancer cells (A549), human hepatoma cells (BEL-7404) and human cervical cancer cells (Hela), and can be expected for antitumor drug purpose.